ArticleRSC advances2026
Integrated network pharmacology, molecular docking, and experimental validation elucidate the anti-inflammatory and antioxidant mechanisms of apigenin in LPS-induced acute lung injury.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are associated with high clinical mortality and lack effective therapeutic agents. The natural flavonoid apigenin possesses well-defined anti-inflammatory and antioxidant activities; however, its protective mechanism in ALI remains to be systematically elucidated. In this study, we established LPS-induced mouse models of ALI and BEAS-2B human bronchial epithelial cell injury models, combined with network pharmacology, molecular docking, and 100 ns molecular dynamics simulations, and employed the ferroptosis inhibitor Fer-1 and inducer Erastin for mechanistic validation, to comprehensively evaluate the protective effects of apigenin. Our results demonstrated that apigenin dose-dependently alleviated pulmonary histopathological damage, reduced inflammatory cell infiltration, myeloperoxidase activity, and the levels of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α. Concurrently, apigenin inhibited the phosphorylation of NF-κB and JAK2-STAT3 pathways, upregulated the expression of GPX4 and SLC7A11, decreased Fe
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.